Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure.
Wyles D, Wedemeyer H, Ben-Ari Z, Gane EJ, Hansen JB, Jacobson IM, Laursen AL, Luetkemeyer A, Nahass R, Pianko S, Zeuzem S, Jumes P, Huang HC, Butterton J, Robertson M, Wahl J, Barr E, Joeng HK, Martin E, Serfaty L; C-CREST Part C and C-SURGE Investigators. Wyles D, et al. Among authors: laursen al. Hepatology. 2017 Dec;66(6):1794-1804. doi: 10.1002/hep.29358. Epub 2017 Oct 30. Hepatology. 2017. PMID: 28688129 Clinical Trial.
Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study.
Hansen N, Obel N, Christensen PB, Kjær M, Laursen AL, Krarup HB, Møller A, Schlichting P, Bukh J, Weis N; Danish Database for Hepatitis B and C (DANHEP)- group. Hansen N, et al. Among authors: laursen al. BMC Infect Dis. 2011 Jun 21;11:177. doi: 10.1186/1471-2334-11-177. BMC Infect Dis. 2011. PMID: 21693019 Free PMC article.
Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.
Sølund C, Krarup H, Ramirez S, Thielsen P, Røge BT, Lunding S, Barfod TS, Madsen LG, Tarp B, Christensen PB, Gerstoft J, Laursen AL, Bukh J, Weis N; DANHEP group. Sølund C, et al. Among authors: laursen al. PLoS One. 2014 Dec 1;9(12):e113034. doi: 10.1371/journal.pone.0113034. eCollection 2014. PLoS One. 2014. PMID: 25438153 Free PMC article.
Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.
Gane EJ, Pianko S, Roberts SK, Thompson AJ, Zeuzem S, Zuckerman E, Ben-Ari Z, Foster GR, Agarwal K, Laursen AL, Gerstoft J, Gao W, Huang HC, Fitzgerald B, Fernsler D, Li JJ, Grandhi A, Liu H, Su FH, Wan S, Zeng Z, Chen HL, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Esteban R. Gane EJ, et al. Among authors: laursen al. Lancet Gastroenterol Hepatol. 2017 Nov;2(11):805-813. doi: 10.1016/S2468-1253(17)30159-0. Epub 2017 Aug 10. Lancet Gastroenterol Hepatol. 2017. PMID: 28802816 Clinical Trial.
Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.
Sølund C, Andersen ES, Mössner B, Laursen AL, Røge BT, Kjær MS, Gerstoft J, Christensen PB, Pedersen MS, Schønning K, Fahnøe U, Bukh J, Weis N. Sølund C, et al. Among authors: laursen al. Eur J Gastroenterol Hepatol. 2018 Oct;30(10):1177-1186. doi: 10.1097/MEG.0000000000001192. Eur J Gastroenterol Hepatol. 2018. PMID: 29994874 Clinical Trial.
Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.
Fahnøe U, Pedersen MS, Sølund C, Ernst A, Krarup HB, Røge BT, Christensen PB, Laursen AL, Gerstoft J, Thielsen P, Madsen LG, Pedersen AG, Schønning K, Weis N, Bukh J. Fahnøe U, et al. Among authors: laursen al. J Viral Hepat. 2021 Feb;28(2):302-316. doi: 10.1111/jvh.13430. Epub 2020 Nov 25. J Viral Hepat. 2021. PMID: 33131178
Alpha interferon therapy in Danish haemophiliac patients with chronic hepatitis C: results of a randomized controlled open label study comparing two different maintenance regimens following standard interferon-alpha-2b treatment.
Laursen AL, Scheibel E, Ingerslev J, Clausen NC, Wantzin P, Ostergaard L, Schou G, Black FT, Krogsgaard K. Laursen AL, et al. Haemophilia. 1998 Jan;4(1):25-32. doi: 10.1046/j.1365-2516.1998.00141.x. Haemophilia. 1998. PMID: 9873862 Clinical Trial.
Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation.
Sølund C, Hallager S, Pedersen MS, Fahnøe U, Ernst A, Krarup HB, Røge BT, Christensen PB, Laursen AL, Gerstoft J, Bélard E, Madsen LG, Schønning K, Pedersen AG, Bukh J, Weis N; DANHEP group. Sølund C, et al. Among authors: laursen al. Scand J Gastroenterol. 2018 Jun-Jul;53(7):849-856. doi: 10.1080/00365521.2018.1467963. Epub 2018 May 2. Scand J Gastroenterol. 2018. PMID: 29720023
145 results